Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Mackinnon

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2017
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan AllograftsKile Green, Kim Pearce, Rob S Sellar, et al.
Blood|April 8, 2010
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioningAdam J Mead, Kirsty J Thomson, Emma C Morris, et al.
Plos One|September 30, 2016
Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive TherapyPaul D Griffiths, Emily Rothwell, Mohammed Raza, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemiaJulio Delgado, Srinivas Pillai, Reuben Benjamin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphomaKirsty J Thomson, Emma C Morris, Don Milligan, et al.
Plos One|September 20, 2017
Correction: Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive TherapyPaul D Griffiths, Emily Rothwell, Mohammed Raza, et al.
Blood|August 12, 2004
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphomaEmma Morris, Kirsty Thomson, Charles Craddock, et al.
Blood|June 6, 2009
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow TransplantationAlexander Claviez, Carme Canals, Daan Dierickx, et al.
British Journal of Haematology|January 9, 2013
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemiaSimon E Richardson, Iftekhar Khan, Andrew Rawstron, et al.
Lancet (London, England)|June 7, 2005
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs, Ann Hunter, Rajesh Chopra, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2017
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan AllograftsKile Green, Kim Pearce, Rob S Sellar, et al.
Blood|April 8, 2010
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioningAdam J Mead, Kirsty J Thomson, Emma C Morris, et al.
Plos One|September 30, 2016
Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive TherapyPaul D Griffiths, Emily Rothwell, Mohammed Raza, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemiaJulio Delgado, Srinivas Pillai, Reuben Benjamin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphomaKirsty J Thomson, Emma C Morris, Don Milligan, et al.
Plos One|September 20, 2017
Correction: Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive TherapyPaul D Griffiths, Emily Rothwell, Mohammed Raza, et al.
Blood|August 12, 2004
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphomaEmma Morris, Kirsty Thomson, Charles Craddock, et al.
Blood|June 6, 2009
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow TransplantationAlexander Claviez, Carme Canals, Daan Dierickx, et al.
British Journal of Haematology|January 9, 2013
Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemiaSimon E Richardson, Iftekhar Khan, Andrew Rawstron, et al.
Lancet (London, England)|June 7, 2005
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantationKarl S Peggs, Ann Hunter, Rajesh Chopra, et al.
Pageof 11